Europe Women’s Health Market Size & Outlook, 2023-2030
Europe women’s health market, 2018-2030 (US$M)
Related Markets
Europe women’s health market highlights
- The Europe women’s health market generated a revenue of USD 12,093.3 million in 2023.
- The market is expected to grow at a CAGR of 6% from 2024 to 2030.
- In terms of segment, contraceptives was the largest revenue generating application in 2023.
- Endometriosis & Uterine Fibroids is the most lucrative application segment registering the fastest growth during the forecast period.
- Country-wise, UK is expected to register the highest CAGR from 2024 to 2030.
Europe data book summary
| Market revenue in 2023 | USD 12,093.3 million |
| Market revenue in 2030 | USD 18,155.3 million |
| Growth rate | 6% (CAGR from 2023 to 2030) |
| Largest segment | Contraceptives |
| Fastest growing segment | Endometriosis & Uterine Fibroids |
| Historical data covered | 2018 - 2022 |
| Base year for estimation | 2023 |
| Forecast period covered | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Hormonal Infertility, Contraceptives, Postmenopausal Osteoporosis, Endometriosis & Uterine Fibroids, Menopause, Polycystic Ovary Syndrome (PCOS) |
| Key market players worldwide | AbbVie Inc, Bayer AG, Merck & Co Inc, Pfizer Inc, Teva Pharmaceutical Industries Ltd, Agile Therapeutics Inc, Amgen Inc, Apothecus, Blairex Laboratories, Ferring |
Other key industry trends
- In terms of revenue, Europe region accounted for 27.3% of the global women’s health market in 2023.
- Globally, North America is projected to lead the regional market in terms of revenue in 2030.
- Asia Pacific is the fastest growing regional market and is projected to reach USD 17,433.6 million by 2030.
Contraceptives was the largest segment with a revenue share of 33.05% in 2023. Horizon Databook has segmented the Europe women’s health market based on hormonal infertility, contraceptives, postmenopausal osteoporosis, endometriosis & uterine fibroids, menopause, polycystic ovary syndrome (pcos) covering the revenue growth of each sub-segment from 2018 to 2030.
The growing population of elderly women is one of the key factors anticipated to increase the prevalence of women’s health issues in Europe. According to Eurostat, approximately 43% of European women are aged above 65.
Various initiatives undertaken by government agencies and NGOs, such as the European Institute of Women’s Health (EIWH) and Women’s Health Organization, to raise awareness about women’s health are anticipated to positively impact the market.
The increasing number of market players involved in manufacturing women's health products in European countries and the growing prevalence of various women’s health issues, such as postmenopausal symptoms, PCOS, & infertility, are anticipated to boost the market. The EMA evaluates the application for human use.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Women’s Health Market Scope
Women’s Health Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Europe women’s health market size, by country, 2018-2030 (US$M)
Europe Women’s Health Market Outlook Share, 2023 & 2030 (US$M)
Related industry reports
Related regional statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
